Chronic lung disease (CLD), formerly known as bronchopulmonary dysplasia, is presently defined as the need for oxygen therapy either at 28 days of age or greater than 36 weeks postmenstrual age. Clinical signs and symptoms include tachypnea, retractions, apnea, and radiographic findings of poorly inflated lungs with reticulogranular opacities. The disease develops as a result of chronic pulmonary inflammation and continuous lung injury induced by oxygen, positive pressure ventilation, and other causes. Fifty to sixty-five percent of neonates with CLD are rehospitalized with respiratory problems, and 21% of very low birth weight neonates are diagnosed with asthma or other respiratory disorders by the age of five. These infants are at risk of adverse neurodevelopmental sequelae as they have a more complicated neonatal course. Many studies have explored various preventive therapies including α1-proteinase inhibitors, superoxide dismutase, antioxidants, and ventilatory management. Although the results from these trials are promising, further studies are needed to define which patients are most likely to benefit from preventive therapy. Two preventive treatment approaches that have shown a decrease in morbidity and an improvement in mortality are antenatal steroids and surfactant therapy. Postnatal corticosteroid therapy continues to be the mainstay of treatment for CLD, however, there are a number of detrimental side effects associated with this treatment. Due to the increased incidence in periventricular leukomalacia, early treatment of steroid therapy cannot be recommended. The optimal time to start steroid therapy appears to be after the first week of life. In addition, the lowest dose and shortest duration of treatment needs to be implemented in order to minimize potential complications. Although bronchodilators and diuretics continue to be used extensively in infants with CLD, there are surprisingly few well-controlled studies that have evaluated the clinical impact of this therapy. Further trials are needed in order to support the routine use of these therapies in CLD. Unfortunately, inhaled steroids have not shown an improvement in long-term outcomes of CLD, however, they have shown a decrease in systemic steroid usage. CLD is a complex disease with many unanswered questions. Further studies are needed to evaluate the effects of various treatment modalities with particular focus on the long-term outcomes such as oxygen and ventilator dependency as well as the incidence of CLD.
Farrell PA, Fiascone PM. Bronchopulmonary dysplasia in the 1990s: a review for the pediatrician. Curr Probl Pediatr. 1997; 27:133-163.
4.
Marshall DD, Kotelchuck M, Young TE. Risk factors for chronic lung disease in the surfactant era: a North Carolina population-based study of very low birth weight infants. Pediatrics. 1999; 104(6):1345-1350.
5.
Lockridge T.Following the learning curve: the evolution of kinder, gentler neonatal respiratory technology. Journal of Obstetric, Gynecologic, and Neonatal Nursing. 1999; 28(4):443-455.
6.
Palta M, Sadek M, Barnet JH, et al. Evaluation of criteria for chronic lung disease in surviving very low birth weight infants. J Pediatr. 1998; 132:57-63.
7.
Witlin AG, Saude GR, Mattar F, et al. Predictors of neonatal outcome in women with severe preeclampsia or eclampsia between 24 and 33 weeks’ gestation. Amer J Obst Gyne. 2000; 182(3):607-611.
8.
Yoon BH, Romero R, Jun JK, et al. Amniotic fluid cytokines and the risk for the development of bronchopulmonary dysplasia. Amer J Obst Gyne. 1997; 177(4):825-830.
9.
Palta M, Gabbert D, Weinstein MR, et al. Multivariate assessment of traditional risk factors for chronic lung disease in very low birth weight neonates. J Pediatr. 1991; 119:285-292.
10.
Ogden BE, Murphy SA, Saunders GC, et al. Neonatal lung neutrophils and elastase/proteinase inhibitor imbalance. Am Rev Resp Dis. 1984; 130:817-821.
11.
Jonsson B, Tullus K, Brauner A, et al. Early increase of TNF-alpha and IL-6 in tracheobronchial aspirate fluid indicator of subsequent chronic lung disease in preterm infants. Arch Dis Child: Fetal and Neonatal Edition. 1997; 77: F198-F201.
12.
Finkelstein JN, Horowitz S, Sinkin RA, et al. Cellular and molecular responses to lung injury in relation to induction of tissue repair and fibrosis. Clinics in Perinatology. 1992; 19:603-620.
13.
DeLemos RA and Coalson JJ. The contribution of experimental models to our understanding of the pathogenesis and treatment of bronchopulmonary dysplasia. Clinics in Perinatology. 1997; 19:521-539.
14.
Horowitz S, Shapiro DL, Finkelstein JN, et al. Changes in gene expression in hyperoxia induced lung injury. American Journal of Physiology. 1990; 258: L107-L111.
15.
Northway WH. An introduction to bronchopulmonary dysplasia. Clinics in Perinatology. 1992; 19:489-495.
16.
Yoon BH, Romero R, Park JS, et al. Fetal exposure to an intra-amniotic inflammation and the development of cerebral palsy at the age of three years. Amer J Obst Gyne. 2000; 182(3):675-681.
17.
Katz-Salamon M, Gerner EM, Jonsson B, et al. Early motor and mental development in very preterm infants with chronic lung disease. Arch Dis Child: Fetal and Neonatal Edition. 2000; 83(1):F1-F6.
18.
Singer L, Yamashita T, Lilien L, et al. A longitudinal study of developmental outcome of infants with bronchopulmonary dysplasia and very low birth weight. Pediatrics. 1997; 100:987-993.
19.
Speer CP, Ruess D, Harms K, et al. Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics. 1993; 91:794-799.
20.
Merritt TA, Cochrane CG, Holcomb K, et al. Elastase and α1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. J Clin Invest. 1983; 72:656-666.
21.
Stiskal JA, Dunn MS, Shennan AT, et al. α1-proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial. Pediatrics. 1998; 101:89-94.
22.
Freeman BA, Young SL, Crapo JD. Liposome-mediated augmentation of superoxide dismutase in endothelial cells prevents oxygen injury. J Biol Chem. 1983; 258:12534-12542.
23.
Frank L, Sosenko IRS. Prenatal development of lung antioxidant enzymes in four species. J Pediatr. 1987; 110:106-110.
24.
Inoue M, Watanabe N, Marino Y, et al. Inhibition of oxygen toxicity by targeting superoxide dismutase to endothelial cell surface. FEBS. 1990; 269:89-92.
25.
Inoue M, Watanabe N, Matsuro K, et al. Expression of a hybrid Cu/Zn-type superoxide dismutase which has high affinity for heparin-like proteoglycans on vascular endothelial cells. J Biol Chem. 1991; 266:16409-16414.
26.
Davis JM, Rosenfeld WN, Richter SE, et al. Safety and pharmacokinetics of multiple doses of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics. 1997; 100(1):24-30.
27.
Shenai JP, Kennedy KA, Chytil F, et al. Clinical trial of vitamin A supplementation in infants susceptible to bronchopulmonary dysplasia. J Pediatr. 1987; 111:269-277.
28.
Kennedy KA, Stoll BJ, Ehrenkranz RA, et al. Vitamin A to prevent bronchopulmonary dysplasia in very-low-birth-weight infants: has the dose been too low?J Early Human Development. 1997; 49:19-31.
29.
Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. N Engl J Med. 1999; 340:1962-1968.
30.
Machlin LJ, Bendich A.Free radical tissue damage: protective role of antioxidant nutrients. FASEB J. 1987; 441-445.
31.
Hallman M, Bry K, Hoppu K, et al. Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med. 1992; 326:1233-1239.
32.
Hallman M, Jarvenpaa AL, Pohjavuori M.Respiratory distress syndrome and inositol supplementation in preterm infants. Arch Dis Child. 1986; 61:1076-1083.
33.
Friedman CA, McVey J, Borne MJ, et al. Relationship between serum inositol concentration and development of retinopathy of prematurity a prospective study. Journal of Pediatric Ophthalmology and Strabismus. 2000; 37(2):79-86.
34.
Burton GW, Ingold KV. Beta carotene: an unusual type of antioxidant. Science. 1984; 224:569-573.
35.
Bose C, Corbet A, Bose G, et al. Improved outcome at 28 days of age for very low birth weight infants treated with a single dose of a synthetic surfactant. J Pediatr. 1990; 117:947-953.
36.
Dekowski SA and Holtzman RB. Surfactant replacement therapy: an update on applications. Pediatrics Clinics of North America. 1998; 45(3):549-572.
37.
Doyle LW, Kitchen WH, Ford GW, et al. Effects of antenatal steroid therapy on mortality and morbidity in very low birth weight infants. J Pediatr. 1986; 108(2):287-292.
38.
Van Marter LJ, Leviton A, Kuban, KC, et al. Maternal glucocorticoid therapy and reduced risk of bronchopulmonary dysplasia. Pediatrics. 1990; 86:331-336.
39.
Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Amer J Obstet Gyne. 1995; 173:322-334.
40.
Doyle LW, Ford GW, Rickards, AL, et al. Antenatal corticosteroids at 14 years of age in children with birth weight less than 1501 grams. Pediatrics. 2000; 106(1):e2:1-9.
41.
Baud O, Foix-L’Helias L, Kaminski M, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999; 341:1190-1196.
42.
Morales WJ, O’Brien WF, Angel JL, et al. Fetal lung maturation: the combined use of corticosteroids and thyrotropin-releasing hormone. Obstet and Gyne. 1989; 73(1):111-115.
43.
Ballard RA, Ballard PL, Cnaan A, et al. Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. N Engl J Med. 1998; 338:493-498.
44.
Collaborative Santiago Surfactant Group. Collaborative trial of prenatal thyrotropin-releasing hormone and corticosteroids for prevention of respiratory distress syndrome. Amer J Obstet Gyne. 1998; 178(1):33-39.
45.
Gonzalo M, Cifuentes J, Carlo WA. Randomized trial of permissive hypercapnia in preterm infants. Pediatrics. 1999; 104(5):1082-1088.
46.
Beresford MW, Shaw NJ, Manning D.Randomised controlled trial of patient triggered and conventional fast rate ventilation in neonatal respiratory distress syndrome. Arch Dis Child. 2000; 82(1): F14-F18.
47.
Baumer JH. International randomised controlled trial of patient triggered ventilation in neonatal respiratory distress syndrome. Arch Dis Child. 2000; 82(1):F5-F10.
48.
Bernstein G, Mannino FL, Heldt GP, et al. Randomized multicenter trial comparing synchronized and conventional intermittent mandatory ventilation in neonates. J Pediatr. 1996; 128:453-463.
49.
Rimensberger PC, Beghetti M, Hanquinet S, et al. First intention high-frequency oscillation with early lung volume optimization improves pulmonary outcome in Very Low Birth Weight Infants with Respiratory Distress Syndrome. Pediatrics. 2000; 105(6):1202-1208.
50.
Gerstmann DR, Minton SD, Stoddard RA, et al. The provo multicenter early high-frequency oscillatory ventilation trial: improved pulmonary and clinical outcome in respiratory distress syndrome. Pediatrics. 1996; 98:1044-1057.
51.
Clark RH, Gerstmann DR, Null DM, et al. Prospective randomized comparison of high-frequency oscillatory and conventional ventilation in respiratory distress syndrome. Pediatrics. 1992; 89:5-12.
52.
Saldanha RL, Cepeda EE, Poland RL. The effect of vitamin E prophylaxis on the incidence and severity of bronchopulmonary dysplasia. J Pediatr. 1982; 101:89-93.
53.
Chandra RK. Nutrition, immunity, and infection. Present knowledge and future directions. Lancet. 1983; 688-691.
54.
Van Aerde JEE, Saver PJJ, Pencharz PB, et al. Effect of replacing glucose with lipid on the energy metabolism of newborn infants. Clin Sci. 1989; 76:581-588.
55.
Watterberg KL, Gerdes JS, Gifford KL, et al. Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatrics. 1999; 104:1258-1263.
56.
Mammel MC, Green TP, Johnson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983; 1356-1358.
57.
O’Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birthweight infants: outcomes of study participants at 1 year adjusted age. Pediatrics. 1999; 104:15-21.
58.
Durand M, Sardesai S, McEvoy C.Effect of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized controlled trial. Pediatrics. 1995; 95:584-590.
59.
Garland JS, Alex CP, Pauly TH, et al. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics. 1999; 104:91-99.
60.
Rastogi A, Akintorin SM, Bez ML, et al. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics. 1996; 98:204-210.
61.
Sinkin RA, Dweck HS, Horgan MJ, et al. Early dexamethasone attempting to prevent chronic lung disease. Pediatrics. 2000; 105:542-548.
62.
Soll RF for the Vermont Oxford Network Steroid Study Group. Early postnatal dexamethasone therapy for the prevention of chronic lung disease. Pediatr Res. 1999; 45:226A.
63.
Brozanski BS, Jones, JG, Gilmour CH, et al. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. J Pediatr. 1995; 126:769-776.
64.
Cummings JJ, D’Eugenio DB, Gross SJ. A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl J Med. 1989; 320:1505-1510.
65.
Papile L, Tyson J, Stoll B, et al. A multicenter trial of two dexamethasone regimens in ventilator-dependent premature infants. N Engl J Med. 1998; 338:1112-1118.
66.
Collaborative Dexamethasone Trial Group. Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Pediatrics. 1991; 88:421-427.
67.
Avery GB, Fletcher AB, Kaplan M, et al. Controlled trial of dexamethasone in reparatory-dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985; 75:106-111.
68.
Harkavy KL, Scanlow JW, Chowdhry PK, et al. Dexamethasone therapy for chronic lung disease in ventilator- and oxygen-dependent infants: a controlled trial. J Pediatr. 1989; 115:979-983.
69.
Kazzi NJ, Brans YW, Poland RL. Dexamethasone effects on the hospital course of infants with bronchopulmonary dysplasia who are dependent on artificial ventilation. Pediatrics. 1990; 86:722-727.
70.
Kothadia JM, O’Shea TM, Roberts D, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birthweight infants. Pediatrics. 1999; 104:22-27.
71.
Halliday HL, Ehrenkranz RA. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. In: The Cochrane Library, Issue 3,2000. Oxford: Updated Software.
72.
Noble-Jamieson CM, Regev R, Silverman M.Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. Eur J Pediatr. 1989; 148:365-367.
73.
Avent M, Gal P, Ranson JL, et al. Evaluating the delivery of nebulized and metered-dose inhalers in an in vitro infant ventilator lung model. Ann Pharmacother. 1999; 33:144-148.
74.
Varsano I, Volovitz B, Malik H, et al. Safety of 1 year of treatment with budesonide in young children with asthma. J Allergy Clin Immunol. 1990; 85:914-920.
75.
Pedersen W, Prahl P.Jet-nebulized beclomethasone dipropionate in the management of bronchial asthma. Allergy. 1987; 42:272-275.
76.
Fok TF, Lam K, Dolovich M, et al. Randomised controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome. Arch Dis Child: Fetal Neonatal Ed. 1999; 80:F203-F208.
77.
Pappagallo M, Abbasi S, Bhutani VK. Respiratory and systemic effects of inhaled dexamethasone on ventilator dependant preterm infants at risk for bronchopulonary dysplasia. Indian J Pediatr. 1998; 65:273-282.
78.
Giep T, Raibble P, Zuerlein T, et al. Trial of beclomethasone dipropionate by metered-dose inhaler in ventilator-dependent neonates less than 1500 grams. American J Perinatology. 1996; 13(1):5-9.
79.
Arnon S, Grigg J, Silverman M.Effectiveness of budesonide aerosol in ventilator-dependent preterm babies: a preliminary report. Pediatr Pulmonol. 1996; 21:231-235.
80.
Kovacs L, Davis GM, Faucher D, et al. Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Acta Paediatr. 1998; 87:792-798.
81.
Cole CH, Colton T, Shaw B, et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med. 1999; 340(13):1005-1010.
82.
LaForce WR, Brudno DS. Controlled trial of beclomethasone dipropionate by nebulization in oxygen- and ventilator-dependent infants. J Pediatr. 1993; 122:285-288.
83.
Merz U, Kusenbach G, Hausler M, et al. Inhaled budesonide in ventilator-dependent preterm infants: a randomized, double-blind pilot study. Biol Neonate. 1999; 75:46-53.
84.
Gal P, Diaz PR, Ransom JL, et al. Beclomethasone for treating premature infants with bronchopulmonary dysplasia. J Pediatr. 1993; 123(3):490-491.
85.
Arnon S, Grigg J, Nikander K, et al. Delivery of micronized budesonide suspension by metered dose inhaler and jet nebulizer into a neonatal ventilator circuit. Pediatr Pulmonol. 1992; 13:172-175.
86.
Brion LP, Primhak RA. Intravenous or enteral loop diuretics in preterm infants with (or developing) chronic lung disease. In: The Cochrane Library, Issue 4, 1999. Oxford: Updated Software.
87.
Kao LC, Warburton D, Sargent CW, et al. Furosemide acutely decreases airway resistance in chronic bronchopulmonary dysplasia. J Pediatr. 1983; 103:624-629.
88.
McCann EM, Lewis K, Deming DD, et al. Controlled trial of furosemide therapy in infants with chronic lung disease. J Pediatr. 1985; 106:957-962.
89.
Najak ZD, Harris EM, Lazzara A, et al. Pulmonary effects of furosemide in preterm infants with lung disease. J Pediatr. 1983; 102:758-763.
90.
Rush MG, Engelhardt B, Parker RA, et al. Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. J Pediatr. 1990; 117:112-118.
91.
Kao LC, Warburton D, Cheng M, et al. Effect of oral diuretics on pulmonary mechanics in infants with chronic bronchopulmonary dysplasia: results of a double-blind crossover sequential trial. Pediatrics. 1984; 74:37-44.
92.
Engelhardt B, Blalock WA, Donlevy S, et al. Effect of spironolactone-hydrochlorothiazide on lung function in infants with chronic bronchopulmonary dysplasia. J Pediatr. 1989; 114:619-624.
93.
Hoffman DJ, Gerdes JS, Abbasi S.Pulmonary function and electrolyte balance following spironolactone treatment in preterm infants with chronic lung disease: a double-blind, placebo-controlled, randomized trial. Journal of Perinatology. 2000; 1:41-45.
94.
Kao LC, Durand DJ, McCrea RC, et al. Randomized trial of long-term diuretic therapy for infants with oxygen-dependent bronchopulmonary dysplasia. J Pediatr. 1994; 124:772-781.
95.
Albersheim SG, Solimano AJ, Sharma AK, et al. Randomized, double-blind, controlled trial of long-term diuretic therapy for bronchopulmonary dysplasia. J Pediatr. 1989; 115:615-620.
96.
Segar JL, Chemtob S, Bell EF. Changes in body water compartments with diuretic therapy in infants with chronic lung disease. Early Human Development. 1997; 48:99-107.
97.
Rastogi A, Luayon M, Ajay O, et al. Nebulized furosemide in infants with bronchopulmonary dysplasia. J Pediatr. 1994; 125:976-979.
98.
Kugelman A, Durand M, Garg M.Pulmonary effect of inhaled furosemide in ventilated infants with severe bronchopulmonary dysplasia. Pediatrics. 1997; 99(1):71-75.
99.
Prabhu V, Keszler M, Dhanireddy R.Pulmonary function changes after nebulised and intravenous frusemide in ventilated premature infants. Arch Dis Child. 1997; 77:F32-F35.
100.
Rush M, Hazinski T.Current therapy of bronchopulmonary dysplasia. Clinics in Perinatology. 1992; 19(3):563-577.
101.
Motoyama EK, Fort MD, Klesh KW, et al. Early onset of airway reactivity in premature infants with bronchopulmonary dysplasia. Am Rev Respir Dis. 1987: 136:50-57
102.
Denjean A, Guimaraes H, Migdal H, et al. Dose-related bronchodilator response to aerosolized salbutamol (albuterol) in ventilator-dependent premature infants. J Pediatr. 1992; 120:974-979.
103.
Carnielli VP, Verlato G, Benini F, et al. Metabolic and respiratory effects of theophylline in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2000; 83:F39-F43.
104.
Wilkie RA, Bryan MH. Effects of bronchodilators on airway resistance in ventilator-dependent neonates with chronic lung disease. J Pediatr. 1987; 111:278-282.
105.
Rotschild A, Solimano A, Puterman M, et al. Increased compliance in response to salbutamol in premature infants with developing bronchopulmonary dysplasia. J Pediatr. 1989; 115:984-991.
106.
Brundage KL, Mohsini KG, Froese AB, et al. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. Am Rev Respir Dis. 1990; 142:1137-1142.
107.
Cabal LA, Larrazabal C, Ramanthan R.Effects of metaproterenol on pulmonary mechanic, oxygenation, and ventilation in infants with chronic lung disease. J Pediatr. 1987; 110:116-119.
108.
Banks BA, Istvan S, Ischiropoulos, et al. Changes in oxygenation with inhaled nitric oxide in severe bronchopulomanry dysplasia. Pediatrics. 1999; 103(3):610-618.
109.
Goodman G, Perkin RM, Anas NG, et al. Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr. 1988; 112:67-72.
110.
Brownlee JR, Beekman RH, Rosenthal A.Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res. 1988; 24:186-190.
